Generex Biotechnology Corporation (GNBT) Receives Regulatory Approval
Generex Biotechnology Corporation (GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that the Ukraine Ministry of Health has issued an approval letter regarding the company's pertinent Phase III clinical trial of Oral-ly. The Ministry specified that the company will be able to conduct their trials at eight clinical sites located in Ukraine. This letter represents the initiation of the first clinical sites for the pivotal study of Oral-ly. Additionally, this particular approval is the first approval from seven countries which Generex seeks to conduct their Phase III trial. The Company has…